AlphaCrest Capital Management LLC decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 60.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,987 shares of the medical research company’s stock after selling 3,073 shares during the quarter. AlphaCrest Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $1,174,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Thermo Fisher Scientific by 16.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,855 shares of the medical research company’s stock valued at $30,628,000 after purchasing an additional 7,238 shares during the last quarter. Kovitz Investment Group Partners LLC increased its holdings in Thermo Fisher Scientific by 1,359.7% in the first quarter. Kovitz Investment Group Partners LLC now owns 10,612 shares of the medical research company’s stock valued at $6,268,000 after buying an additional 9,885 shares during the last quarter. Marietta Wealth Management LLC raised its stake in Thermo Fisher Scientific by 4.3% in the first quarter. Marietta Wealth Management LLC now owns 12,912 shares of the medical research company’s stock valued at $7,626,000 after buying an additional 529 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Thermo Fisher Scientific by 0.6% during the 4th quarter. California State Teachers Retirement System now owns 708,079 shares of the medical research company’s stock worth $472,459,000 after acquiring an additional 4,340 shares in the last quarter. Finally, Kingfisher Capital LLC increased its holdings in shares of Thermo Fisher Scientific by 1.6% in the 1st quarter. Kingfisher Capital LLC now owns 8,200 shares of the medical research company’s stock valued at $4,843,000 after acquiring an additional 133 shares during the last quarter. Institutional investors and hedge funds own 86.50% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on TMO shares. Morgan Stanley upped their price target on Thermo Fisher Scientific from $670.00 to $678.00 and gave the company an “overweight” rating in a report on Friday, July 29th. SVB Leerink increased their target price on shares of Thermo Fisher Scientific from $630.00 to $650.00 and gave the company an “outperform” rating in a research report on Friday, July 29th. Barclays boosted their price target on shares of Thermo Fisher Scientific to $685.00 in a research report on Tuesday, August 9th. Finally, Credit Suisse Group initiated coverage on Thermo Fisher Scientific in a research report on Wednesday, August 24th. They set a “neutral” rating and a $675.00 target price on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $662.07.
Insider Buying and Selling at Thermo Fisher Scientific
Thermo Fisher Scientific Stock Performance
Shares of TMO opened at $543.55 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $497.83 and a 1 year high of $672.34. The stock has a market capitalization of $212.96 billion, a P/E ratio of 28.93, a P/E/G ratio of 1.74 and a beta of 0.83. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.13 and a current ratio of 1.65. The company’s fifty day moving average is $565.76 and its two-hundred day moving average is $557.74.
Thermo Fisher Scientific (NYSE:TMO – Get Rating) last posted its quarterly earnings results on Thursday, July 28th. The medical research company reported $5.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.92 by $0.59. Thermo Fisher Scientific had a net margin of 17.37% and a return on equity of 24.36%. The firm had revenue of $10.97 billion during the quarter, compared to analysts’ expectations of $9.95 billion. During the same period in the prior year, the company posted $5.60 earnings per share. The firm’s revenue for the quarter was up 18.3% on a year-over-year basis. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 22.92 earnings per share for the current year.
Thermo Fisher Scientific Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 14th. Shareholders of record on Thursday, September 15th will be given a $0.30 dividend. This represents a $1.20 annualized dividend and a yield of 0.22%. The ex-dividend date of this dividend is Wednesday, September 14th. Thermo Fisher Scientific’s payout ratio is 6.39%.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
- Get a free copy of the StockNews.com research report on Thermo Fisher Scientific (TMO)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.